A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advance Solid Tumors · Colon and Rectal Cancer · Non - Small Cell Lung Cancer NSCLC · Pancreatic Adenocarcinoma Advanced or Metastatic · Ovarian Cancer · Endometrial Cancer · Biliary Cancers

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Ruihua Xu) · Xurh@sysucc.org.cn · +86 181 2791 2755
Contact: Principal Investigator (Ruihua Xu, MD, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Malignant Head and Neck Neoplasm · Malignant Neoplasm · Metastatic Malignant Neoplasm in the Neck

Abroad (travel likely)Recruiting

Houston, United States

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Advance Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Santa Monica, United States · Camperdown, Australia

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Solid Tumor

Abroad (travel likely)RecruitingPHASE1

Washington D.C., United States